Could a diabetes drug help heart failure patients with valve replacements?

NCT ID NCT07610174

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looked at whether adding semaglutide (a drug used for diabetes and weight loss) to the standard heart failure medication dapagliflozin helps people with heart failure who have had a surgical heart valve replacement. 160 participants were split into two groups: one got the combination therapy, the other continued dapagliflozin alone. Researchers tracked changes in heart function, symptoms, and quality of life to see if the combo offers extra benefits.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
semaglutide
What this could lead to
If it works, this could point toward a new combination treatment to improve heart function and quality of life for heart failure patients with valve replacements.
What could go wrong
This is a small, early-phase proof-of-concept trial, so results may not be definitive. The combination may not provide additional benefit over standard care and could cause side effects like nausea or gastrointestinal issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kafrelsheikh univeristy hospital, Faculty of medicine, Kafrelsheikh univeristy

    Kafr ash Shaykh, Kafrelsheikh Governrate, 33511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.